Abbvie Inc. failed to defeat a proposed class action by a Chicago-area technician who says he and other workers were ...

Local pharmaceutical giant AbbVie is suing drug manufacturer BeiGene over allegedly stealing trade secrets to develop a competing cancer drug following the hiring of a longtime AbbVie research ...

AbbVie’s Skyrizi has been approved by the FDA as a treatment for ulcerative colitis, making it the first IL-23 inhibitor indicated for both major types of inflammatory bowel disease (IBD ...

AbbVie's IL-23 inhibitor Skyrizi trailed some of its rivals in its first indication psoriasis, but has leapfrogged into first place in Crohn's disease after getting approval for the new indication ...

AbbVie's nonprofit foundation is partnering with health care incubator Matter on a new accelerator to advance solutions to improve care for underserved communities. The AbbVie Foundation Health ...

Sept 9 (Reuters) - Pharmaceutical giant AbbVie (ABBV.N), opens new tab has sued cancer treatment maker BeiGene (6160.HK), opens new tab in Chicago federal court, accusing it of stealing trade ...

AbbVie reported Thursday that its experimental Parkinson’s drug that it got from Cerevel Therapeutics helped alleviate symptoms and improve quality of life in a late-stage study. In the Phase 3 ...

One of the world's top biopharma companies, AbbVie (NYSE: ABBV) is a fairly complicated stock to approach as an independent investor. Aside from the scientific chops needed to evaluate the quality ...

Vandana Singh TransDigm, BJ's Wholesale, AbbVie And More On CNBC's 'Final Trades' TransDigm Group (TDG), BJ's Wholesale (BJ), VanEck Semiconductor ETF (SMH), and AbbVie (ABBV) were recommended as ...

Given its better valuation, we believe that Pfizer stock (NYSE: PFE) is currently a better pick than its industry peer – AbbVie stock . PFE stock trades at a much lower multiple of 11x forward ...

AbbVie ABBV stock has gained 19.4% in the past three months compared with an increase of 8.1% for the industry. The stock has also outperformed the sector and S&P 500 index as seen in the chart ...

AbbVie (ABBV) closed the latest trading day at $196.42, indicating a +1.56% change from the previous session's end. This change outpaced the S&P 500's 1.16% gain on the day. Elsewhere, the Dow saw ...